AstraZeneca has paid out more than $2 billion in penalties and settlements since 2000 across at least 34 enforcement actions, and it continues to face active lawsuits over its COVID-19 vaccine, a Chinese fraud investigation, shareholder claims, drug patents, and the federal 340B pricing program. The largest resolved matters are a $520 million federal off-label marketing settlement over Seroquel in 2010 and a $425 million product liability settlement over Nexium and Prilosec in 2023. Below is where each major AstraZeneca lawsuit stands as of the most recent available reporting.
Seroquel Off-Label Marketing: $520 Million
In April 2010, AstraZeneca agreed to pay $520 million to resolve federal and state allegations that it illegally marketed the antipsychotic Seroquel for uses the FDA had not approved. The Department of Justice said the company promoted the drug between 2001 and 2006 for anxiety, depression, dementia, ADHD, PTSD, anger management, and sleeplessness, none of which were approved indications.1U.S. Department of Justice. AstraZeneca Seroquel Settlement Press Release
Prosecutors alleged the marketing caused false claims to be submitted to Medicare, Medicaid, TRICARE, and the VA, and that the company violated the Anti-Kickback Statute by paying doctors to speak on unapproved uses, flying physicians to resort locations under the guise of advisory meetings, and recruiting doctors to attach their names to ghostwritten journal articles. Roughly $302 million went to the federal government and up to $218 million to state Medicaid programs. The case began as a False Claims Act whistleblower suit, and AstraZeneca entered a five-year Corporate Integrity Agreement.1U.S. Department of Justice. AstraZeneca Seroquel Settlement Press Release
Nexium and Prilosec Kidney Injury: $425 Million
In October 2023, AstraZeneca agreed to pay $425 million to settle roughly 11,000 lawsuits alleging that its proton pump inhibitors Nexium and Prilosec caused chronic kidney disease, kidney damage, or kidney failure. The claims, consolidated in New Jersey federal court starting in 2017, accused the company of failing to warn patients about the risks for both prescription and over-the-counter versions. AstraZeneca did not admit wrongdoing.2Reuters. AstraZeneca to Pay $425 Million to Settle Nexium, Prilosec Litigation in US
The AstraZeneca deal was the largest piece of a broader $590.4 million resolution that also involved GlaxoSmithKline, Procter & Gamble, Pfizer, and Takeda. The multidistrict litigation before Judge Claire Cecchi in the District of New Jersey was listed as resolved by May 2025.3Seeger Weiss LLP. Proton Pump Inhibitor Litigation
Seroquel XR Pay-for-Delay: $50.9 Million
In a separate matter involving the same drug family, AstraZeneca reached a $50.9 million settlement in 2025 to resolve antitrust claims that it conspired to delay cheaper generic versions of Seroquel XR, the extended-release quetiapine used for schizophrenia and bipolar disorder. The case, In re Seroquel XR Antitrust Litigation (No. 1:20-cv-01076), was filed in the District of Delaware and litigated for nearly six years.4Bloomberg Law. AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit
Direct purchasers alleged AstraZeneca and Handa Pharmaceuticals entered unlawful reverse-payment agreements, in which a brand-name manufacturer pays a generic competitor to stay off the market. The settlement class covers entities that purchased Seroquel XR or its generic equivalent for members, employees, or insureds between September 2015 and December 2024 in qualifying states.5Seroquel XR Antitrust Settlement. Frequently Asked Questions As of mid-2025, the settlement awaited final approval from Judge Colm Connolly.6PYMNTS. AstraZeneca Agrees to $50.9 Million Settlement in Antitrust Case Over Schizophrenia Drug
COVID-19 Vaccine Injury Cases
AstraZeneca’s COVID-19 vaccine, Vaxzevria, supplied more than three billion doses globally before the company withdrew it worldwide in May 2024, citing a surplus of updated vaccines and falling demand.7Reuters. AstraZeneca to Withdraw COVID Vaccine Worldwide A rare blood-clot risk was identified in 2021, and AstraZeneca acknowledged in court filings that the vaccine could in rare cases cause Thrombosis with Thrombocytopenia Syndrome.8CNBC. AstraZeneca to Withdraw COVID Vaccine Worldwide, Citing Drop in Demand
United Kingdom
The law firm Leigh Day represents 50 individuals and families in a UK product liability claim brought under the Consumer Protection Act 1987. It focuses on Vaccine Induced Immune Thrombosis with Thrombocytopenia, or VITT. Although AstraZeneca is the named defendant, the UK government indemnified the company during the pandemic and is effectively funding both the defense and any award. The case is ongoing, expected to reach trial in 2025 or 2026, with no specific trial date publicly confirmed. Leigh Day is also pushing to raise the UK Vaccine Damage Payment Scheme’s £120,000 cap, unchanged since 2010.9Leigh Day. AstraZeneca COVID-19 Vaccine Claim
United States
In the U.S., clinical trial participant Brianne Dressen was diagnosed with post-vaccine neuropathy by the National Institutes of Health in June 2021. She alleges AstraZeneca broke a contractual promise to cover her medical costs for trial-related injuries. AstraZeneca argues it is immune under the Public Readiness and Emergency Preparedness Act, which broadly shields pandemic countermeasure makers. A federal judge in Utah denied the company’s motion to dismiss the breach of contract claim in November 2024. The Tenth Circuit heard oral arguments on November 19, 2025, and had not ruled as of the most recent reporting.10Courthouse News Service. AstraZeneca Takes a Shot at Immunity From COVID Injury Case
China Fraud Investigation
Chinese authorities opened investigations into AstraZeneca’s China operations starting in 2024 that led to the detention of Leon Wang, the company’s China president and executive vice president for international markets, in approximately November 2024. Two current and two former senior executives were also detained. The investigations concern alleged illegal importation of the cancer drugs Enhertu and Imjudo from Hong Kong into mainland China before mainland approval, improper collection of patient data, and medical insurance fraud tied to manipulated genetic testing results used to boost sales of the lung cancer drug Tagrisso.11Fierce Pharma. AstraZeneca Stock Tanks Over Fears of Expanding China Fraud Probe
The insurance-fraud thread originated as early as 2022 with employees in Shenzhen and grew to reach senior regional sales executives. In November 2025, Chinese authorities formally charged Wang with medical insurance fraud, illegal trade, and unlawful collection of personal information. The case remains active.12Pamir Law Group. What the Indictment of Former AstraZeneca Executive Means for Multinational Pharmaceutical Companies in China
CEO Pascal Soriot said publicly that the investigations targeted specific individuals rather than the company, stating, “We have very little information because we haven’t been approached as a company so far.” AstraZeneca said it was cooperating with authorities and had added field-based compliance officers and AI tools to monitor expense reports.13The Guardian. AstraZeneca China Investigation
Shareholder Securities Class Action
The China matter triggered a U.S. shareholder class action. In Jeries Saleh v. AstraZeneca PLC (No. 2:24-cv-11021), filed in the Central District of California, investors allege AstraZeneca and senior executives Pascal Soriot and Aradhana Sarin made materially false and misleading statements by failing to disclose the China insurance fraud, Wang’s detention, and the related legal and business risks. The proposed class covers investors who bought AstraZeneca American Depositary Shares on NASDAQ between February 23, 2022, and December 17, 2024.14DiCello Levitt. DiCello Levitt Named Lead Counsel in Shareholder Class Action Against AstraZeneca In March 2025, Judge John F. Walter appointed a group of institutional investors as lead plaintiff and DiCello Levitt as lead counsel. The case is in early stages.15Midpage. Jeries Saleh v. AstraZeneca PLC
Medicare Drug Price Negotiation Challenge
AstraZeneca mounted a constitutional challenge to the Inflation Reduction Act’s Drug Price Negotiation Program after its diabetes drug Farxiga was selected for negotiation for the 2026 pricing period. The company argued the program violated the Fifth Amendment’s Due Process Clause by imposing price controls without adequate procedural safeguards, barring judicial review of key agency decisions, and threatening excise tax penalties as high as 1,900% of a drug’s price for manufacturers that refused to negotiate.16Supreme Court of the United States. AstraZeneca Pharmaceuticals LP v. Kennedy, Petition for Writ of Certiorari
The District of Delaware ruled against AstraZeneca in March 2024, and the Third Circuit affirmed on May 8, 2025, holding that AstraZeneca lacked standing on its Administrative Procedure Act claims and had no protected property interest in selling drugs to Medicare beneficiaries at a specific price. The court rejected the argument that Medicare drug transactions are “private market transactions,” treating them instead as reimbursements within a public-private structure.17U.S. Court of Appeals for the Third Circuit. AstraZeneca Pharmaceuticals LP v. Secretary of HHS, No. 24-1819 The Supreme Court denied certiorari on May 18, 2026, ending the challenge.18SCOTUSblog. AstraZeneca Pharmaceuticals LP v. Kennedy
Alexion FCPA Settlement
AstraZeneca acquired Alexion Pharmaceuticals in 2021, inheriting a Foreign Corrupt Practices Act settlement Alexion had reached with the SEC the year before. In July 2020, Alexion agreed to pay approximately $21.4 million to resolve charges that its subsidiaries bribed government officials in multiple countries to help its rare-disease drug Soliris.19SEC. SEC Filing Regarding Alexion
The SEC found that in Turkey, an Alexion subsidiary funneled more than $1.3 million to a consultant who used it to provide cash, gifts, and meals to Ministry of Health officials in exchange for influencing Soliris prescription approvals. In Russia, the subsidiary paid more than $1 million to healthcare providers at state-owned institutions with authority over regional budgets. In Brazil and Colombia, employees directed the creation of inaccurate financial records regarding payments to patient advocacy organizations. The Department of Justice closed its parallel inquiry without bringing separate charges.19SEC. SEC Filing Regarding Alexion
Patent Disputes on Blockbuster Drugs
Two of the most closely watched patent fights concern AstraZeneca’s top oncology products.
On Enhertu, Seagen (now part of Pfizer) had won a $41.82 million jury verdict plus ongoing royalties against Daiichi Sankyo and AstraZeneca on a patent related to the antibody-drug conjugate. In December 2025, the Federal Circuit reversed, ruling Seagen’s patent invalid for failing to meet written description and enablement requirements. The damages and infringement finding were vacated. The deadline for further review passed in March 2026, concluding the dispute.20Daiichi Sankyo. Patent Dispute Between Daiichi Sankyo and Seagen Has Concluded
On Tagrisso, a jury had awarded Wyeth, a Pfizer unit, $107.5 million after finding the lung cancer drug infringed two Wyeth patents. In August 2024, the District of Delaware vacated the verdict, holding the patents invalid for lack of enablement and written description. Wyeth appealed; the Federal Circuit heard argument in May 2026, and a decision is pending.21Law360. Wyeth LLC v. AstraZeneca Pharmaceuticals LP Patent litigation involving Lokelma, Lynparza, Soliris, Forxiga, and Calquence is also active in the U.S., UK, and Europe.19SEC. SEC Filing Regarding Alexion
340B Drug Pricing Fights
AstraZeneca is a party to multiple lawsuits over the federal 340B Drug Pricing Program, which requires manufacturers to give steep discounts to safety-net hospitals and clinics. The company has sued at least seven states, including Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and West Virginia, challenging state laws that protect 340B contract pharmacy arrangements. In one such case, the District of Hawaii denied AstraZeneca’s request for a preliminary injunction in February 2026.22American Hospital Association. 8th Circuit Upholds Arkansas Law Protecting 340B Contract Pharmacy Arrangements
In a related antitrust class action, health centers accused AstraZeneca and other insulin manufacturers of conspiring to restrict 340B-discounted insulin sales through contract pharmacies. A district court dismissed the case, but in August 2025 the Second Circuit vacated the dismissal, finding the plaintiffs alleged enough facts to support a plausible inference of horizontal price-fixing. The appeals court sent the case back so plaintiffs could file an amended complaint.23Health Law Diagnosis. Appellate Court Gives Go-Ahead for 340B Contract Pharmacy Insulin Pricing Suit to Proceed
The Overall Enforcement Record
According to the Violation Tracker database maintained by Good Jobs First, AstraZeneca has accumulated more than $2 billion in total penalties across 34 recorded enforcement actions since 2000. The largest categories are safety-related offenses ($623 million), healthcare-related offenses ($594 million), government-contracting violations ($556 million), and competition-related offenses ($235 million). The Seroquel off-label settlement remains the single largest penalty, followed by the Nexium and Prilosec product liability settlement.24Good Jobs First Violation Tracker. AstraZeneca Violation Tracker